Multiple-Drug Resistant Enterococci: The Nature of the Problem and an Agenda for the Future
Mark M. Huycke*†, Daniel F. Sahm‡, and Michael S. Gilmore†
Author affiliations: *University of Oklahoma Health Sciences Center, Oklahoma, USA; †Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA; ‡MLR Pharmaceutical Services, Inc., Reston, Virginia, USA
Figure 3. Cytolysin favors the appearance of circulating enterococci. In this experiment, 107 CFU of E. faecalis, either cytolytic FA2-2(pAM714) (60) or noncytolytic FA2-2(pAM771) (64), were intraperitoneally injected (45) into groups of five BalbC mice. Viable bacteria in liver, spleen, and the bloodstream were enumerated 48 hrs following injection, and significance assessed by Student's t-test. (P. Coburn, L.E. Hancock, and M.S. Gilmore, in preparation).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.